Akero Therapeutics price target raised to $35 from $30 at BofA

BofA raised the firm’s price target on Akero Therapeutics (AKRO) to $35 from $30 and keeps a Neutral rating on the shares after updating the firm’s model for the “quiet” third quarter. Material updates were “admittedly light,” but the firm thought Akero’s Q3 update was “positive overall,” the firm stated. The firm now forecasts 2025 EPS of ($4.57), versus ($4.36) previously, the analyst noted.